Roswell Park Comprehensive Cancer Center has formed an academic cooperation with the Jagiellonian University in Kraków.
The collaboration will see the two centers exchanging staff, students and scientific resources to undertake basic, translational and clinical research in order to advance the development of cancer therapies.
The agreement grew out of a July 2018 visit by Polish Secretary of State Anna Maria Anders to Roswell Park. Four Roswell Park faculty leaders, joined by Anders, recently traveled to Kraków to initiate the collaboration: Kunle Odunsi, deputy director, chair of gynecologic oncology and executive director of the Center for Immunotherapy; Pawel Kalinski, vice chair for translational research and Rustum Family Professor for Molecular Therapeutics and Translational Research; Agnieszka Witkiewicz, director of the Center for Personalized Medicine and chief for research in the Department of Pathology; and Danuta Kozbor, associate professor of immunology and microbiology.
The agreement is effective immediately, and could see exchange of students and faculty between the two centers as early as spring 2019.
Roswell Park partners with Jagiellonian University in Kraków
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
YOU MAY BE INTERESTED IN
Stepping into the NCI director’s job at the end of a nerve-racking year, Anthony Letai wants you to know that the federal government is not going out of the business of cancer research.


Anthony G. Letai’s initiation as the 18th director of the National Cancer Institute wasn’t exactly smooth.


After three weeks of brutal combat, Richard Pazdur decided that he has had enough.


As a gastroenterologist, I’ve had the sobering experience of delivering a colorectal cancer diagnosis for far too many patients and family members. Some meant to get screened but never found the time. Others thought it didn’t apply to them or assumed it would be too inconvenient.


Imaging assessments are a requirement for most oncology trial endpoints. Yet, many cancer centers are still trying to support research trials with clinical care tools and ad hoc processes that are not fit-for-purpose and don’t meet the needs of sponsors or trial staff.





